(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 February 2020 (20.02.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/037024 A1

(51) International Patent Classification:
A61K 47/48 (2006.01)

(21) International Application Number:
PCT/US2019/046467

(22) International Filing Date:
14 August 2019 (14.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/765,093 16 August 2018 (16.08.2018) US

(71) Applicant: **GENMAB A/S** [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK).

(72) Inventor; and
(71) Applicant *(for BW only)*: **RANGWALA, Reshma A.** [US/US]; c/o Genmab US, Inc., 902 Carnegie Center, Suite 301, Princeton, New Jersey 08540 (US).

(72) Inventors: **BREIJ, Esther C.W.**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **VERPLOEGEN, Sandra**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **DE GOEIJ, Bart**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **ABIDOYE, Oyewale O.**; 11012 SE 64th Street, Bellevue, Washington 98006 (US). **NICACIO, Leonardo V.**; 17409 NE 116th Way, Redmond, Washington 98052 (US). **ALLEY, Stephen C.**; c/o Seattle Genetics, Inc., 21823 30th Drive, S.E., Bothell, Washington 98021 (US).

(74) Agent: **BANKO, Max** et al.; Morrison & Forester LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2020/037024 A1

(54) **Title:** ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER




FIG. 3

(57) **Abstract:** The invention provides methods and compositions for treating cancer, such as ovarian cancer, peritoneal cancer, and fallopian tube cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (*e.g.*, ovarian cancer, peritoneal cancer, and fallopian tube cancer).